ALISHA MOORE: Open Payments
NPI 1710407150 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$588 in 32 payments from 14 companies in 2025. Trend: 2023 $661 · 2024 $547 · 2025 $588
Food & beverage: $588
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $182 |
| Dexcom, Inc. | 5 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Abbott Laboratories | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 1 | $37 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $20 |
Products named: Wegovy, Dexcom G6 Transmitter, REXULTI, CAPLYTA, Ozempic, FREESTYLE LIBRE 3, FANAPT, Kerendia.
Industry payments across AL — which companies pay providers there.
